Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group upgraded Galmed Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, July 24th. View Our Latest Stock […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Millennium Management ,Galmed Pharmaceuticals ,Maxim Group ,Galmed Pharmaceuticals Company Profile ,Raymond James Financial Services Advisors Inc ,Cambridge Investment Research Advisors Inc ,Galmed Pharmaceuticals Ltd ,Institutional Investors Weigh In On Galmed Pharmaceuticals ,Galmed Pharmaceuticals Stock ,News Ratings For Galmed Pharmaceuticals Daily ,Free Report ,Get Free Report ,James Financial Services Advisors ,Investment Research Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,